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Abstract
Introduction: Osteoarthritis (OA) is a common joint disease that can cause gradual disability among the
aging population. Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) is a key transcription factor that regulates the
expression of phase II antioxidant enzymes that provide protection against oxidative stress and tissue damage.
The use of histone deacetylase inhibitors (HDACi) has emerged as a potential therapeutic strategy for various
diseases. They have displayed chondroprotective effects in various animal models of arthritis. Previous studies
have established that Nrf2 acetylation enhances Nrf2 functions. Here we explore the role of Nrf2 in the
development of OA and the involvement of Nrf2 acetylation in HDACi protection of OA.
Methods: Two OA models—monosodium iodoacetate (MIA) articular injection and destabilization of the medial
meniscus (DMM)—were used with wild-type (WT) and Nrf2-knockout (Nrf2-KO) mice to demonstrate the role of
Nrf2 in OA progression. A pan-HDACi, trichostatin A (TSA), was administered to examine the effectiveness of HDACi
on protection from cartilage damage. The histological sections were scored. The expression of OA-associated matrix
metalloproteinases (MMPs) 1, 3, and 13 and proinflammatory cytokines tumor necrosis factor (TNF)-α, interleukin (IL)-1β,
and IL-6 were assayed. The effectiveness of HDACi on OA protection was compared between WT and Nrf2-KO mice.
Results: Nrf2-KO mice displayed more severe cartilage damage in both the MIA and DMM models. TSA promoted the
induction of Nrf2 downstream proteins in SW1353 chondrosarcoma cells and in mouse joint tissues. TSA also reduced
the expression of OA-associated proteins MMP1, MMP3, and MMP13 and proinflammatory cytokines TNF-α, IL-1β,
and IL-6. TSA markedly reduced the cartilage damage in both OA models but offered no significant protection in
Nrf2-KO mice.
Conclusions: Nrf2 has a major chondroprotective role in progression of OA and is a critical molecule in HDACi-mediated
OA protection.
Introduction
Osteoarthritis (OA) is a common joint disease and the
major cause of disability among the aging population. OA
is characterized by progressive degradation in articular car-
tilage, periarticular bone, synovial joint lining, and adjacent
supporting connective tissue elements, which eventually
results in a loss of joint function [1]. Although many etio-
logical factors contribute to OA disease progression, such
as hereditary, metabolism, and mechanical stress [2, 3], the
exact mechanism of OA remains unclear. Currently, there
are no satisfactory drugs for effective treatment of OA, and
total joint replacement has to be considered in severe cases.
Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) is a key
transcription factor that regulates the antioxidant defense
system. Nrf2 activates its downstream gene expression by
controlling the antioxidant response elements (AREs)
located in the promoter regions of its target genes, includ-
ing antioxidative enzyme heme oxygenase 1 (HO-1) and
NAD(P)H:quinine oxidoreductase 1 (NQO1) [4]. Nrf2 ac-
tivity is regulated by various protein modification processes,
such as Keap1-mediated ubiquitinated degradation, protein
kinase C/mitogen-activated protein kinase (MAPK)-medi-
ated phosphorylation [5, 6], and histone acetyltransferase
(HAT)/histone deacetylase (HDAC)-mediated acetylation
[7]. Nrf2 acetylation enhances its transcription capacity and
downstream target expression and has been shown to con-
fer protection in animal models of inflammation- and oxi-
dative stress-related disease [7, 8].
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HDACs can alter the acetylation status of histone and
non-histone proteins and can regulate many physiological
and pathological processes. Histone deacetylase inhibitors
(HDACi) have therapeutic potential in various diseases
[9–11]. Inhibition of HDACs causes hyperacetylation of
the target proteins and leads to an alteration of gene ex-
pression involved in cell differentiation, proliferation, or
apoptosis [12]. Mounting evidence demonstrates that
HDACi prevent degradation of cartilage in animal models
of OA [13–16], suggesting that HDACs have a protective
role in OA. However, the molecular mechanisms under-
lying the action of HDACi in OA have not been fully
elucidated.
Because Nrf2 and its downstream proteins are protective
in OA-related joint damage and Nrf2 acetylation enhances
Nrf2 functions, we hypothesize that Nrf2 acetylation plays
an essential role in the protective effects of HDACi in OA.
In this study, we explored the role of Nrf2 in the develop-
ment of OA and the involvement of Nrf2 in the protective
effects of HDACi in OA. We used two OA mouse mod-
els—monosodium iodoacetate (MIA) articular injection
and destabilization of the medial meniscus (DMM)—to test
the role of Nrf2 in the progression of OA. We further
determined the requirement of Nrf2 in HDACi protection
from OA in both MIA and DMM mice. Our results dem-
onstrate that Nrf2 plays a major chondroprotective role in
the progression of OA and is a critical mediator in HDACi
protection from OA damage.
Methods
Reagents
Trichostatin A (TSA), MIA, and mouse recombinant
interleukin (IL)-1β were obtained from Sigma-Aldrich (St.
Louis, MO, USA). Anti-matrix metalloproteinase (anti-
MMP)-13, anti-MMP-3, anti-MMP-1, and anti-histone 3
antibodies were obtained from Santa Cruz Biotechnology
(Santa Cruz, CA, USA). Anti-HO-1, anti-NQO1, and anti-
Nrf2 antibodies were purchased from Bioworld Technology
(Nanjing, China). Antiacetylated Nrf2 (K599) was obtained
from ImmunoWay Biotechnology (Newark, DE, USA), and
antiacetylated histone H3 was purchased from EMD Milli-
pore (Billerica, MA, USA).
Animals
Nrf2-KO male mice (used with permission from Dr.
Yamamoto Masayuki) and their wild-type (WT) littermates
at 8–10 weeks of age were used in the experiments. Mice
were fed a regular sterile chow diet and allowed access to
water ad libitum, and they were housed under controlled
conditions (25 ± 2 °C; 12-h light-dark cycle). All experimen-
tal protocols were approved by the Institutional Animal
Care and Use Committee (IACUC) of Nanjing University
Medical School and were carried out in accordance with
Nanjing University Medical School IACUC guidelines.
Genotypes of WT and Nrf2-KO mice were confirmed by
polymerase chain reaction (PCR) of genomic DNA isolated
from mouse tail (Fig. 1g). PCR amplification was carried
out by using one common forward primer, a WT-specific
reverse primer, and an Nrf2-KO–specific reverse primer in
one PCR. The primer sequences are listed in Table 1.
Models of osteoarthritis
MIA model
The MIA model of OA was adapted from a previous
study [17]. Briefly, the mouse right knee joint was flexed
at a 90-degree angle, and 6 μl of 5 mg/ml MIA dissolved
in sterile saline (0.9 %) was injected into the joint
capsule with a 30-gauge needle. Intra-articular injection
of saline into the left knee was performed as a control.
Three weeks later, the mice were killed for joint and
other analysis.
DMM model
The experimental mice were anesthetized with peritoneal
injection of ketamine (50 mg/kg), and DMM surgery was
performed with a microsurgical knife on the right knee by
sectioning of the medial meniscotibial ligament (MMTL)
that anchored the medial meniscus (MM) to the tibial
plateau. The lateral meniscotibial ligament was identified
and protected during the surgery. Contralateral knee
joints received sham surgery in which the MMTL was ex-
posed without sectioning. Mice were allowed completely
free movement following DMM surgery. Six weeks later,
the mice were killed and their knee joints were harvested
for histological analysis and other examinations.
Cell culture
SW1353 human chondrosarcoma cells were grown in
Dulbecco’s modified Eagle’s medium supplemented with
10 % fetal bovine serum and 100 U/ml penicillin. Cells
were maintained at 37 °C in a humidified incubator under
a 5 % CO2 atmosphere. Cells were treated with different
doses of TSA or in combination with IL-1β and then fur-
ther examined.
Treatment of TSA
TSA was administrated by subcutaneous injection daily
(2.0 mg/kg) for 3 weeks in the MIA model and for 6 weeks
in the DMM model. TSA was dissolved in alcohol initially
and then diluted with phosphate-buffered saline (PBS) to a
final working concentration of 0.1 μg/μl before use [9, 10].
Control mice received the same amount of PBS injection.
At the end of the experiment, the mice were killed with
CO2 inhalation and their knee joints were collected and
stored at −80 °C until further analysis.
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Histological assessment
Mouse knee joints were prepared for histological assess-
ment. Briefly, the knee joints were prepared by removing
skin and muscle and then immediately fixed in 4 % para-
formaldehyde. The knee joints were further decalcified in
20 % formic acid and embedded in paraffin. Frontal serial
sections (5 μm thick) across entire joints were obtained,
and 10 slides per joint at every 50 μm were selected and
stained with Safranin O/Fast Green to assess cartilage
destruction.
The Osteoarthritis Research Society International
(OARSI) scoring system (grade 0: surface intact, cartilage
intact; grade 1: surface intact; grade 2: surface discon-
tinuity; grade 3: vertical fissures; grade 4: erosion; grade
5: denudation; grade 6: deformation) was used to assess
the joint cartilage degeneration [18]. The maximum
score (the highest score in either quadrant of femur or
tibia) and the summed score (the sum of the highest
scores in all four quadrants of knee joint: medial femoral
condyle, lateral femoral condyle, medial tibial plateau,
and lateral tibial plateau) were used to measure the
extent of cartilage destruction [18, 19].
RT-PCR and qRT-PCR
Total RNA was extracted from cultured chondrocytes using
TRIzol reagent (Invitrogen, Carlsbad, CA, USA). cDNA
was synthesized from total RNA using a reverse transcript-
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Fig. 1 Nrf2-KO mice display more severe articular cartilage damage in osteoarthritis (OA) animal models. a Nrf2-KO and wild-type (WT) mice were subject
to monosodium iodoacetate (MIA) OA. Mouse joint sections were stained with Safranin O/Fast Green. Representative images are shown (n = 10 mice per
group). Lower panels show amplifications of upper panel insets. Yellow arrows point to the damage-affected cartilage areas. b Summed scores of femur and
tibia damage in WT and Nrf2-KO mice in the MIA model. *p< 0.05, **p< 0.01. c Maximum scores of femur and tibia damage from WT and Nrf2-KO mice
of MIA model. *p< 0.05, ** p< 0.01. d Nrf2-KO and WT mice were subject to DMM surgery. Mouse joint sections were stained with Safranin O/Fast Green
and the representative images were shown (n = 10 mice per group). Lower panels were the amplifications of windows from upper panels. The yellow
arrows indicate the damage-affected cartilage areas. e Summed scores of femur and tibia damage from WT and Nrf2-KO mice of DMM model. *p< 0.05,
**p< 0.01. f Maximum scores of femur and tibia damage from WT and Nrf2-KO mice of DMM model. *p< 0.05, ** p< 0.01. g PCR genotyping of WT and
Nrf2-KO mice on mouse tail DNA. h Western blot analysis of heme oxygenase 1 (HO-1) and NAD(P)H:quinine oxidoreductase 1 (NQO1) from mouse joint
tissues of WT and Nrf2-KO mice (three mice in each group). i Quantitative analysis of HO1 and NQO1 protein levels. *p< 0.05, **p< 0.01. jWestern blot
analysis of matrix metalloproteinases MMP-1, MMP-3, and MMP-13 from the joint tissues of WT and Nrf2-KO mice (three mice in each group). k Quantitative
analysis of MMP-1, MMP-3, and MMP-13 protein levels. *p< 0.05. KO knockout, Nrf2 nuclear factor (erythroid-derived 2)-like 2
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USA) according to the manufacturer’s recommendations.
The cDNA was amplified by PCR using specific primers
and Taq DNA polymerase (Vazyme Biotech). PCR was pre-
ceded for 30–35 cycles in a TC-412 thermocycler (Techne/
Bibby Scientific, Stone, UK).
Quantitative real-time PCR (qRT-PCR) was performed
with cells and joint tissues. Total RNA was extracted from
mouse knee cartilage following homogenization in TRIzol
reagent. Reverse transcription was performed with l μg of
RNA in a total 20-μl reaction using PrimeScript RT
Master Mix (Clontech Laboratories, Mountain View, CA,
USA) according to the manufacturer’s instructions. qRT-
PCR experiments were done with a 7500 real-time PCR
system (Applied Biosystems, Waltham, MA, USA) using
SYBR Premix Ex Taq reagents (TaKaRa, Shiba, Japan). All
data were normalized to β-actin. All assays were done in
triplicate. The specific primer sets for qRT-PCR are listed
in Table 1.
Cartilage extraction and Western blot analysis
Cartilage tissue was removed surgically and pulverized in
liquid nitrogen shortly thereafter, then stored at −80 °C
until analysis. For Western blot analysis, the cartilage
tissue was extracted in PBS containing 1 % Triton X-100,
0.1 % SDS, 20 nM sodium orthovanadate, 1 μg/ml aproti-
nin, 1 mM phenylmethylsulfonyl fluoride, and 5 mM
ethylenediaminetetraacetic acid. The homogenates were
centrifuged at 12,000 × g for 30 minutes at 4 °C, and the
protein concentration in the supernatant was measured
using a bicinchoninic acid assay kit (Pierce Biotechnology/
Thermo Scientific, Rockford, IL, USA), Equal amounts of
protein from each animal cartilage were solubilized in lysis
buffer containing 10 mM Tris-HCl (pH 7.5), 1 mM ethyl-
ene glycol tetraacetic acid, 1 mM MgCl2, 1 mM sodium
orthovanadate, 1 mM dithiothreitol, 0.1 % mercaptoetha-
nol, 0.5 % Triton X-100, and protease inhibitor cocktail.
Proteins were separated by SDS-PAGE and transferred
onto a polyvinylidene difluoride membrane. The mem-
branes were blocked with 5 % milk resolved in Tris-
buffered saline–Tween 20 buffer, followed by Western
blotting with antibodies at predetermined dilutions.
Luciferase assays
An HO-1 promoter–luciferase reporter plasmid [20] was
used to test Nrf2 signaling activity. HEK293 cells were
cotransfected with the reporter plasmid and a Renilla lucif-
erase reporter plasmid by using Lipofectamine 2000 reagent
(Invitrogen). On the next day, the cells were treated with
TSA for 12 h, and a luciferase assay system (Promega,
Madison, WI, USA) was used to measure luciferase activity.
The relative luciferase activity in each sample was
determined by subtracting the background firefly lu-
ciferase activity and normalized to Renilla luciferase
activity. All reported assays were repeated at least
three times independently.
Statistical analysis
Data were expressed as mean ± standard deviation. Differ-
ences between groups were compared by Student’s t test or
Mann-Whitney U test. Analyses were performed using
GraphPad Prism 4.0 software (GraphPad Software, La Jolla,
CA, USA). A p value < 0.05 was considered statistically
significant. A p value < 0.01 was considered statistically
very significant.
































GAPDH glyceraldehyde 3-phosphate dehydrogenase, HO-1 heme oxygenase
1, IL interleukin, MMP matrix metalloproteinase, NQO1 NAD(P)H:quinine
oxidoreductase 1, Nrf2 nuclear factor (erythroid-derived 2)-like 2; Nrf2-KO
Nrf2-knockout, qRT-PCR quantitative real-time polymerase chain reaction,
RT-PCR reverse transcription polymerase chain reaction, TNF tumor necrosis
factor, WT wild type
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Results
Nrf2-KO mice display accelerated progression of articular
cartilage destruction in MIA and DMM models
To investigate whether Nrf2 mediates HDACi protection
against OA, we first tested the role of Nrf2 in the devel-
opment of OA in the MIA model. WT and Nrf2-KO
mice were genotyped by PCR (Fig. 1g). Both WT and
Nrf2-KO mice (10 mice in each group) received joint in-
jections of MIA for 3 weeks before being killed. The
joint sections were stained with Safranin O/Fast Green.
Both WT and Nrf2-KO mice developed arthritis charac-
terized by loss of joint cartilage and exposed subchon-
dral bone with dense sclerosis. Compared with WT
mice, Nrf2-KO mice showed much severer cartilage
damage (Fig. 1a). To quantify the severity of the joint
damage, we analyzed histopathological changes using
the OARSI scoring system. WT mice displayed summed
arthritic scores of 10.40 ± 6.58 for the femur and 11.75 ±
2.79 for the tibia. The summed scores of Nrf2-KO mice
were significantly higher at 17.25 ± 5.76 for the femur
and 19.20 ± 8.21 for the tibia (*p < 0.05, **p < 0.01)
(Fig. 1b). WT mice had maximum scores of 2.15 ± 1.00 for
the femur and 2.50 ± 0.55 for the tibia. The maximum
scores of Nrf2-KO mice were also significantly higher (3.65
± 1.45 for the femur and 3.85 ± 1.05 for the tibia; *p < 0.05,
**p < 0.01) (Fig 1c).
To confirm the importance of Nrf2 in the develop-
ment of OA, we used another model of OA: a DMM
model. We performed DMM surgery in the right knee
joints of WT and Nrf2-KO mice (10 mice in each
group). Six weeks later, the mouse knee joints were sub-
ject to histological analysis and the cartilage damage
caused by instability was observed in the medial com-
partment when WT and Nrf2-KO mice were compared
(Fig. 1d). WT mice displayed summed arthritic scores of
8.00 ± 4.45 for the femur and 10.65 ± 3.04 for the tibia.
In contrast, Nrf2-KO mice showed significantly higher
summed scores, with 14.15 ± 4.81 for the femur and
18.35 ± 2.56 for the tibia (*p < 0.05, **p < 0.01) (Fig. 1e).
WT mice had maximum scores of 2.85 ± 1.70 for the
femur and 3.15 ± 0.74 for the tibia. The maximum scores
of Nrf2-KO mice were also significantly higher (femur
4.45 ± 1.25, tibia 5.15 ± 0.98; *p < 0.05, **p < 0.01)
(Fig. 1f ).
We next examined the expression of two Nrf2
downstream proteins: HO-1 and NQO1. The expres-
sion of HO-1 and NQO1 was enhanced in OA cartil-
age (Fig. 1h, i), indicating that the Nrf2 signaling
pathway was activated in OA. In addition, the ex-
pression of MMP-1, MMP-3, and MMP-13 was also
increased in OA cartilage compared with the control
cartilage (Fig. 1j, k). Taken together, these results
indicate that Nrf2 is chondroprotective during the
development of OA.
HDAC inhibition activates Nrf2 signaling pathway in
chondrocytes in vitro
To test whether HDACi regulate Nrf2 signaling in chon-
drocytes, we examined the effect of TSA on the expression
of Nrf2 downstream proteins in human chondrosarcoma
SW1353 cells. The results showed that TSA induced the
expression of the Nrf2 downstream proteins HO-1 and
NQO1 in a dose- and time-dependent manner (Fig. 2a–c).
TSA also induced marked histone 3 acetylation, as expected
(Fig. 2a, lower panel). TSA treatment caused Nrf2 nuclear
translocation (Fig. 2d, e) and activated the HO-1 promoter
transactivation activity (Fig. 2f). To examine the effect of
HDACi on OA-related protein expression, we used IL-1β
to induce MMP expression in SW1353 cells. The results
showed that TSA treatment suppressed IL-1β–induced
MMP-1, MMP-3, and MMP-13 expression at both the
mRNA and protein levels (Fig. 2g–i), indicating that
HDACi could effectively activate Nrf2 signaling and sup-
press OA-related MMP expression in chondrocytes.
TSA alleviates OA-related cartilage damage
To determine the protective property of HDACi on OA,
we first tested the effect of TSA in the MIA model. TSA
treatment alone did not cause an observable arthritis-like
change to mouse knees (Fig. 3a). We injected MIA into
mouse knees in the presence or absence of TSA (2 mg/kg/
day subcutaneously) for a period of 3 weeks. We then
examined the knee joint histology by Safranin O/Fast
Green staining. TSA significantly decreased the cartilage
damage in the medial tibial plateau and femoral condyle
(Fig. 3a, arrowheads). To better observe the tide mark and
chondrocyte proliferation (cell clusters), we also per-
formed hematoxylin and eosin staining, which clearly
showed that the location of the tide mark in the MIA
group was much closer to the articular surface, especially
in the lateral femoral condyle of both femur and tibia,
whereas the TSA-treated group displayed a much im-
proved tide mark location and cell clusters (data not
shown). Overall, the MIA group had summed scores of
10.33 ± 3.59 for the femur and 12.25 ± 3.84 for the tibia,
whereas the TSA-treated group exhibited significantly
lower values of 4.83 ± 3.13 for the femur and 6.17 ± 3.27
for the tibia (p < 0.05) (Fig. 3b). When the maximum
score analysis was applied, TSA treatment demonstrated
similar improvements. The MIA group had maximum
scores of 2.08 ± 0.67 for the femur and 2.42 ± 0.53 for the
tibia, whereas the TSA-treated group had significantly
lower values of 0.92 ± 0.67 for the femur and 1.33 ± 0.69
for the tibia (p < 0.05) (Fig. 3c).
We also performed the experiments in the DMM
model, TSA (2 mg/kg/day subcutaneously) was delivered
for 6 weeks following surgical sectioning of the MMTL.
TSA markedly relieved the cartilage damage (Fig. 3d).
The DMM group had summed scores of 7.33 ± 3.35 for
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the femur and 8.17 ± 2.73 for the tibia, whereas the
TSA-treated group exhibited significantly lower values
of 2.00 ± 1.26 for the femur and 2.92 ± 0.84 for the tibia
(p < 0.05) (Fig. 3e). The DMM group had maximum
scores of 1.92 ± 0.84 for the femur and 2.5 ± 1.35 for the
tibia, whereas the TSA-treated group had significantly
lower values of 0.75 ± 0.48 for the femur and 1.17 ± 0.24
for the tibia (p < 0.05) (Fig. 3f ). These results indicate
that TSA prevention of cartilage damage was not model-
dependent.
TSA improves OA-associated protein expression
To estimate the involvement of the Nrf2 pathway in TSA
protection of OA, we assayed Nrf2 downstream genes
HO-1 and NQO1. TSA treatment enhanced the expression
of HO-1 and NQO1 in MIA mice (Fig. 4a). TSA treatment
also suppressed OA-induced MMP-1, MMP-3, and
MMP-13 expression (Fig. 4b) and significantly reduced
tumor necrosis factor (TNF)-α (Fig. 4c), IL-1β (Fig. 4d),
and IL-6 (Fig. 4e) levels. In addition, TSA treatment
caused enhanced Nrf2 and histone 3 acetylation in mouse
joints (Fig. 4f). These results demonstrate that HDACi-
improved cartilage histology is associated with HDACi
enhancement of tissue-protective molecules and repression
of MMPs and proinflammatory cytokines. TSA protection
of OA was correlated with its HDAC inhibition property,
as it increased Nrf2 and histone 3 acetylation.
TSA protection of OA requires Nrf2
We next decided to determine whether Nrf2 was required
for the HDACi protection. We injected MIA into both WT
and Nrf2-KO mice and treated mice with TSA as before. In
WT mice, TSA significantly reduced cartilage damage,
including hypocellularity and loss of proteoglycans; how-
ever, TSA failed to reduce the joint damage in Nrf2-KO
mice (Fig. 5). Similarly to previous results, WT mice had
summed scores of 11.00 ± 3.65 for the femur and 13.50 ±
5.23 for the tibia, whereas TSA treatment led to a signifi-
cant improvement of 5.33 ± 2.19 for the femur and 6.92 ±
4.24 for the tibia (p < 0.05) (Fig. 4b). When the maximum
scores were applied, WT mice scored 2.17 ± 0.80 for the
femur and 2.67 ± 0.99 for the tibia, whereas TSA showed
significantly lower scores of 1.00 ± 0.58 for the femur and
1.25 ± 0.63 for the tibia (p < 0.05) (Fig. 4c). However, in
Nrf2-KO mice, TSA treatment led to only a marginal
reduction of joint cartilage damage (Fig. 5d). Nrf2-KO mice
A
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Fig. 2 Trichostatin A (TSA) activates nuclear factor (erythroid-derived 2)-like 2 (Nrf2) and suppresses matrix metalloproteinase (MMP) expression in
human chondrocytes. a SW1353 chondrosarcoma cells were treated with various doses of TSA for 16 h. Heme oxygenase 1 (HO-1), NAD(P)H:quinine
oxidoreductase 1 (NQO1), and acetylated histone 3 (ac-H3) were assayed by Western blotting. β-actin and total histone 3 were used as loading controls.
b Quantitative analysis of HO-1 and NQO1 protein levels. *p< 0.05 compared with control. c SW1353 chondrosarcoma cells were treated with TSA (10 nM)
for various times. HO-1 and NQO1 were assayed by Western blotting. d SW1353 chondrosarcoma cells were treated with TSA (10 nM) for 4 h. The cell
cytoplasmic and nuclear fractions were isolated and assayed for Nrf2 by Western blotting. β-actin, total Nrf2, and lamin B from total cell lysates served as
controls. e Quantitative analysis of cytoplasmic and nuclear Nrf2 from (d). *p< 0.05 compared with no-treatment controls. f HEK293 cells were transiently
transfected with HO-1 promoter reporter plasmid and a Renilla luciferase plasmid for 24 h. The cells were then treated with 10 nM and 30 nM of TSA for
24 h. The luciferase activity was measured. The reporter luciferase activities were normalized to Renilla luciferase activity. *p< 0.05, **p< 0.01 compared with
no-treatment control. g SW1353 chondrosarcoma cells were treated with increasing concentrations of TSA for 1 h and then stimulated with interleukin
(IL)-1β (5 ng/ml) for 16 h. MMP-1, MMP-3, and MMP-13 were assayed by RT-PCR. h MMP-1, MMP-3, and MMP-13 were assayed by Western blotting.
i Quantitative analysis of MMP-1, MMP-3, and MMP-13 levels from (h). *p< 0.05 compared with IL-1β treatment only. All the Western blotting and RT-PCR
results are representative of, and the statistical analyses were performed with results from, at least three independent experiments
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showed summed scores of 18.17 ± 7.20 for the femur and
20.42 ± 8.65 for the tibia, but TSA treatment only slightly
reduced the scores to 14.17 ± 6.39 for the femur and
17.33 ± 10.73 for the tibia (Fig. 5b). Nrf2-KO mice
had maximum scores of 3.50 ± 1.41 for the femur and
3.83 ± 1.57 for the tibia. TSA treatment was associated
with similar scores of 3.25 ± 1.87 for the femur and
3.33 ± 1.57 for the tibia (Fig. 5c), indicating that TSA
provided no protection against cartilage damage of
OA in mice that lacked Nrf2. These results strongly
indicate that TSA protects against cartilage damage in
OA through regulation of Nrf2.
We observed similar histological changes in the DMM
model (Fig. 5d). Among WT mice, the OA group had
summed scores of 7.67 ± 3.35 for the femur and 9.08 ±
3.22 for the tibia, whereas TSA treatment exhibited sig-
nificantly lower values of 3.00 ± 2.31 and 3.33 ± 0.94, re-
spectively (p < 0.05 and p < 0.01) (Fig. 5e). The OA
group had maximum scores of 2.17 ± 0.90 for the femur
and 2.67 ± 1.18 for the tibia, whereas the TSA-treated
group had significantly lower values of 0.92 ± 0.79 and
1.25 ± 0.48, respectively (p < 0.05) (Fig. 5f ). In contrast
to TSA alleviation of cartilage destruction in WT mice,
TSA treatment neither improved cartilage degradation
nor changed the scores significantly in Nrf2-KO mice
(Fig. 5e, f, right panels).
We also tested the MMP-1, MMP-3, MMP-13, HO-1,
and NQO1 mRNA levels in cartilage by qRT-PCR. The re-
sults showed that TSA treatment significantly suppressed
the induction of MMP-1, MMP-3, and MMP-13 (Fig. 5g)
and enhanced the expression of HO-1 (Fig. 5h) and NQO1
(Fig. 5i) in WT mice, but it did not significantly change
these levels in Nrf2-KO mice. Consistent with the histo-
pathological changes, Nrf2-KO mice displayed significantly
higher levels of MMP-1, MMP-3, and MMP-13 than WT
mice, highlighting these MMPs’ destructive role in OA.
Discussion
HDACi have been used in various animal models of







Fig. 3 Trichostatin A (TSA) attenuates cartilage damage in monosodium iodoacetate (MIA) osteoarthritis (OA) and destabilization of the medial
meniscus (DMM) OA models. a Histology of joints in the MIA OA model. Osteoarthritis was induced in mice by MIA articular injection. TSA was
delivered via subcutaneous injection (2.0 mg/kg/day). Three weeks later, the joint sections were stained with Safranin O/Fast Green. Representative
images of mouse joints are shown (n = 6 mice per group). Lower panels show amplifications of upper panel insets. Yellow arrows indicate
the damage-affected cartilage areas. b Summed scores for femur and tibia. *p < 0.05. c Maximum scores for femur and tibia. *p < 0.05.
d Histology of joints in the DMM model. Wild-type and nuclear factor (erythroid-derived 2)-like 2–knockout mice were subjected to DMM.
TSA was administrated daily (2.0 mg/kg/day) for 6 weeks. The mouse joints were stained with Safranin O/Fast Green. Representative images
are shown (n = 6 mice per group). Lower panels show amplifications of upper panel insets. Yellow arrows indicate the damage-affected
cartilage areas. e Summed scores for femur and tibia. *p < 0.05. f Maximum scores for femur and tibia. *p < 0.05
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pathogenesis. Although many contributing factors and/
or molecules are proposed to account for the protective
mechanisms of HDACi, we found in this study that Nrf2
acts upstream of the signaling and plays an indispensable
role in HDACi-mediated protection against OA.
OA is one of the most common aging-related joint dis-
eases, and the molecular mechanisms of OA are not yet
fully known [21]. Excessive oxidative stress is associated
with OA and triggers the programmed cell death or ne-
crosis of chondrocytes during OA [22]. Proinflammatory
cytokines such as TNF-α, IL-1β, IL-6, and MMPs also play
major roles in OA pathogenesis [23, 24]. Nrf2 transcrip-
tion factor is a master regulator of antioxidative stress.
Nrf2 signaling regulates the expression of antioxidant-
responsive genes and phase II detoxifying enzymes that
counteract the oxidative damage in tissue injury [4]. The
Nrf2 pathway also crosstalks with inflammatory signaling
pathways such as the MAPK and nuclear factor κB
pathways and negatively regulates inflammatory responses
[25, 26]. Therefore, Nrf2 is expected to provide protection
against OA injury. Previous studies demonstrated that
Nrf2 was activated in the joints of mice and patients with
rheumatoid arthritis and that depletion of Nrf2 accelerated
joint inflammation and cartilage destruction in animals
with rheumatoid arthritis [27, 28]. Although rheumatoid
arthritis and OA share many common features of joint
damage, they represent different etiological processes. We
employed two OA animal models—namely, DMM and
MIA—to verify the critical role of Nrf2 in OA development
and progression. The DMM model is one of the most com-
monly used surgical OA models. In the DMM model, the
traumatic injury causes a progressive degeneration of cartil-
age, subchondral bone sclerosis, and osteophyte formation,
which mimic the pathological changes observed in human
OA [29, 30]. The MIA model represents the chemical
induction of OA by intra-articular injection of MIA. MIA
inhibits glyceraldehyde 3-phosphate dehydrogenase activity
in chondrocytes and results in cell death following the
disruption of the cellular glycolysis process [31]. The cartil-
age degenerative changes in MIA are comparable to those
of human OA, including structural changes such as lack of
surface regularities, cartilaginous matrix collapse, and cartil-
age fibrillation as well as functional changes such as reduc-
tion in the compressive stiffness of the articular cartilage
[32]. We demonstrated in both DMM and MIA models
that Nrf2 downstream proteins HO-1 and NQO1 were
upregulated in OA. More importantly, mice lacking Nrf2
developed much more severe joint damage, as judged by
histological examination and the summed and maximum
score analyses (Fig. 1a–d). These results indicate that, simi-
larly to the mouse model of rheumatoid arthritis, the Nrf2
pathway exerts a major protective function in OA develop-
ment and pathogenesis.
Recent studies have revealed that Nrf2 is a protein
acetylation target. Nrf2 acetylation increases its signaling
and enhances its downstream gene expression [7, 8]. We
previously showed that HDACi induced Nrf2 acetylation
and alleviated the stroke-related brain inflammatory
A B
C D E F
Fig. 4 Trichostatin A (TSA) improves the expression of osteoarthritis (OA)-associated proteins and the induction of inflammatory cytokines in
monosodium iodoacetate (MIA) OA mice. a Western blot analysis of heme oxygenase 1 (HO-1) and NAD(P)H:quinine oxidoreductase 1 (NQO1)
from joints of MIA-OA or TSA-treated MIA-OA wild-type (WT) mice. The quantification was done on the right side. *p < 0.05, **p < 0.01 compared
with MIA-OA mice. b Western blot analysis of matrix metalloproteinases MMP-1, MMP-3, and MMP-13 from joints of MIA-OA and TSA-treated
MIA-OA WT mice. The quantification was done on the right side. **p < 0.01 compared with MIA-OA mice. Quantitative real-time polymerase chain
reaction analysis of tumor necrosis factor (TNF)-α (c), interleukin (IL)-1β (d), and IL-6 (e) from joint tissues of MIA-OA or TSA-treated MIA-OA WT
mice. *p < 0.05, **p < 0.01 compared with MIA-OA mice. f Western blot analysis of acetylated nuclear factor (erythroid-derived 2)-like 2 (Ac-Nrf2)
and acetylated histone 3 (ac-H3) from MIA-OA or TSA-treated MIA-OA WT mice (three mice in each group). Total Nrf2 and histone 3 served as
internal controls. All the Western blot analysis results are representative of, and the statistical analyses were performed with results from, at least
six animals
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damage [20]. In the present study, we confirmed that the
HDACi TSA promoted Nrf2 nuclear translocation, in-
creased expression of Nrf2 target genes HO-1 and NQO1,
and activated HO-1 promoter transactivation in chondro-
cytes (Fig. 2a–d), suggesting that TSA-induced Nrf2 acetyl-
ation might contribute to HDACi protection in OA. In the
following experiments, we confirmed that TSA enhanced
expression of Nrf2 downstream proteins HO-1 and NQO1
in mouse joints and effectively reduced cartilage damage in
both MIA- and DMM-treated mice. Cartilage degradation
is a hallmark of OA and is caused partially by the excess
deposition of cartilage proteoglycan-degrading enzymes
such as MMPs [33–35]. Proinflammatory cytokines also
promote cartilage injuries [36]. Researchers in previous
studies have reported that HDACi repressed MMPs and
proinflammatory cytokine expression in joints and reduced
the severity of cartilage lesions [13, 14, 37]. We also found
that TSA effectively reduced the levels of MMP-1, MMP-3,
MMP-13, TNF-α, IL-1β, and IL-6 in mouse joints (Fig. 3).
In light of the fact that upregulation of Nrf2 downstream
proteins such as HO-1 can reduce the expression of MMPs
and inhibit the production of proinflammatory cytokines
[38–40], it is reasonable to attribute the inhibition of MMPs
and proinflammatory cytokines, at least partially, to the
HDACi-induced Nrf2 signaling activation. Also, because
HO-1 and the other Nrf2 target proteins are major
defenders in tissue repair [41], we speculate that HDACi-
induced Nrf2 activation is the major contributor to the
improved joint histology. However, it is worth noting that







Fig. 5 Trichostatin A (TSA) protection of osteoarthritis (OA) requires nuclear factor (erythroid-derived 2)-like 2 (Nrf2). a Wild-type (WT) and Nrf2-knockout
(Nrf2-KO) mice were subjected to monosodium iodoacetate (MIA)-induced OA or MIA-induced OA with or without TSA treatment (n = 10 in each group).
Mouse joint sections were stained with Safranin O/Fast Green. Representative images are shown. Lower panels show amplifications of upper panel insets.
Yellow arrows indicate the damage-affected cartilage areas. b Summed scores of femur and tibia damage in WT and Nrf2-KO mice with MIA-induced OA.
*p< 0.05. c Maximum scores representing femur and tibia damage in WT and Nrf2-KO mice with MIA-induced OA. *p< 0.05. dWT and Nrf2-KO mice were
subjected to destabilization of the medial meniscus (DMM)-induced OA or to DMM-induced OA with or without TSA treatment (n = 10 in each group).
Mouse joint tissue sections were stained with Safranin O/Fast Green. Representative images are shown. Lower panels show amplifications of upper panel
insets. Yellow arrows indicate the damage-affected cartilage areas. e Summed scores of femur and tibia damage in WT and Nrf2-KO mice with DMM-
induced OA. *p< 0.05, **p< 0.01 compared with OA group. f Maximum scores of femur and tibia damage in WT and Nrf2-KO mice with DMM-induced
OA. *p< 0.05. g Quantitative real-time polymerase chain reaction (qRT-PCR) analysis of matrix metalloproteinases MMP-1, MMP-3, and MMP-13 from joints
of WT and Nrf2-KO mice with MIA-induced OA or TSA-treated MIA-induced OA. *p< 0.05, **p< 0.01 compared with MIA-OA mice. qRT-PCR analysis of
HO-1 (h) and NQO1 (i) from joints of WT and Nrf2-KO mice with MIA-OA or TSA-treated OA. *p< 0.05, **p< 0.01 compared with MIA-OA mice
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(around 8 weeks old) and had immature skeletons. We
therefore cannot exclude the possibility that other late
developmental events might affect the effectiveness of
HDACi and Nrf2 dependency in these two OA models.
Future study is needed to examine whether HDACi has
similar protective effects in older mice.
To conclusively determine the role of Nrf2 acetylation
in HDACi protection against OA, we further compared
the effect of TSA on cartilage destruction between WT
and Nrf2-KO mice. Our results showed that, although
TSA still markedly reduced OA cartilage damage in WT
mice, it did not significantly improve the joint injury in
Nrf2-KO mice in either the MIA or the DMM model
(Fig. 5), indicating that Nrf2 is essential for HDACi-
mediated cartilage protection. Previous studies have shown
that various types of pan-HDACi and specific HDAC
subtype inhibition provide protection against OA injuries
[13–16]; however, the acetylation target molecules and the
signaling pathways involved are largely unknown. HDACs
can either modify non-histone signal molecules, such as
Nrf2 in the present study, or target chromatin histones in-
dependently to affect gene transcription. HDAC inhibition
can also promote signaling molecule association with HAT,
bringing HAT to the target gene promoter and subse-
quently affecting target gene transcription [42]. Our results
show that Nrf2-KO mice are not protected by TSA (Fig. 5),
suggesting that Nrf2 represents a convergence between
Nrf2 acetylation and HDACi actions through which HDAC
inhibition provides protection against OA.
Conclusions
We explored the effectiveness of HDACi in protection
against OA in two animal models and identified Nrf2 as
the critical molecule mediating HDACi protection. Our
study improves understanding of OA pathogenesis and
provides novel insights into the development of HDACi-
based therapeutic strategies.
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